TW249226B - - Google Patents

Info

Publication number
TW249226B
TW249226B TW081106617A TW81106617A TW249226B TW 249226 B TW249226 B TW 249226B TW 081106617 A TW081106617 A TW 081106617A TW 81106617 A TW81106617 A TW 81106617A TW 249226 B TW249226 B TW 249226B
Authority
TW
Taiwan
Prior art keywords
cataract
medicament
manufacture
treatment
ketoprostaglandin compound
Prior art date
Application number
TW081106617A
Other languages
English (en)
Chinese (zh)
Original Assignee
Aderk Ueno Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aderk Ueno Kk filed Critical Aderk Ueno Kk
Application granted granted Critical
Publication of TW249226B publication Critical patent/TW249226B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW081106617A 1990-04-04 1991-03-28 TW249226B (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9089590 1990-04-04
JP22164690 1990-08-22
JP2931091 1991-01-29

Publications (1)

Publication Number Publication Date
TW249226B true TW249226B (enExample) 1995-06-11

Family

ID=27286510

Family Applications (2)

Application Number Title Priority Date Filing Date
TW081106617A TW249226B (enExample) 1990-04-04 1991-03-28
TW080102419A TW224942B (enExample) 1990-04-04 1991-03-28

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW080102419A TW224942B (enExample) 1990-04-04 1991-03-28

Country Status (11)

Country Link
US (2) US5212324A (enExample)
EP (1) EP0453127B1 (enExample)
KR (1) KR970005172B1 (enExample)
AT (1) ATE169219T1 (enExample)
AU (1) AU644148B2 (enExample)
CA (1) CA2039420C (enExample)
DE (1) DE69129921T2 (enExample)
DK (1) DK0453127T3 (enExample)
ES (1) ES2119762T3 (enExample)
GR (1) GR3027666T3 (enExample)
TW (2) TW249226B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (enExample) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
DE69434617D1 (de) * 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
SE9403160D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
KR19990036322A (ko) * 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
CA2303764C (en) * 1997-09-09 2005-02-15 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
ID24845A (id) * 1997-09-09 2000-08-24 Procter & Gamble Prostaglandin tetrahidro tersubstitusi c16-c20 aromatik yang berguna sebagai agonis fp
DK0978284T3 (da) * 1997-11-28 2008-10-27 Sucampo Ag Anvendelse af 15-keto-prostaglandin-E-forbindelser som endothelinantagonister
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
BR0109192A (pt) * 2000-03-16 2003-05-27 Sucampo Ag Tratamento de hipertensão ocular e glaucoma.
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
TWI284535B (en) 2000-03-24 2007-08-01 Sucampo Ag Apoptosis inhibitor
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
ATE433754T1 (de) 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
BR0205932A (pt) * 2001-08-23 2004-02-17 Sucampo Ag Método e composição para tratamento de hipertensão ocular e glaucoma
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
US8580851B2 (en) * 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
JP4889219B2 (ja) 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
JP5222462B2 (ja) 2003-08-21 2013-06-26 スキャンポ・アーゲー 眼科用組成物
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
JP4690814B2 (ja) * 2004-08-02 2011-06-01 株式会社アールテック・ウエノ プロスタグランジン誘導体の製造法
JP5147404B2 (ja) 2005-01-27 2013-02-20 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
AU2006219152B2 (en) 2005-03-04 2011-02-24 Sucampo Ag Method and composition for treating peripheral vascular diseases
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
KR101466980B1 (ko) * 2005-04-12 2014-12-01 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자펌프 억제제의 병용
CN104983712A (zh) * 2006-01-24 2015-10-21 株式会社·R-技术上野 软明胶胶囊制剂
BRPI0707333B8 (pt) 2006-01-24 2021-05-25 R Tech Ueno Ltd composição farmacêutica que compreende um composto bicíclico, método de estabilização do composto bicíclico e formulação de cápsula de gelatina mole
WO2007105691A1 (ja) 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CN103561748A (zh) 2011-04-07 2014-02-05 苏坎波公司 治疗眼疲劳的方法
CA2842455A1 (en) 2011-08-05 2013-02-14 Sucampo Ag Method for treating schizophrenia
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
US20170020890A1 (en) 2015-06-19 2017-01-26 Sucampo Ag Pharmaceutical composition comprising fatty acid derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505386A (en) * 1965-12-29 1970-04-07 Upjohn Co Compounds related to prostaglandins
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
EP0292177B1 (en) * 1987-05-15 1992-03-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Fervescence composition
GB2209939B (en) * 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
EP0310305B1 (en) * 1987-10-02 1992-07-22 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Cathartics
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
ES2055051T3 (es) * 1988-05-23 1994-08-16 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para la fabricacion de un medicamento eficaz para aumentar la presion sanguinea.
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP0366279B1 (en) * 1988-10-01 1994-09-21 R-Tech Ueno Ltd. Ocular hypotensive agents
TW205508B (enExample) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo

Also Published As

Publication number Publication date
KR910018027A (ko) 1991-11-30
EP0453127A3 (en) 1992-12-09
GR3027666T3 (en) 1998-11-30
CA2039420C (en) 1996-12-10
DE69129921T2 (de) 1999-01-14
US5212324A (en) 1993-05-18
KR970005172B1 (ko) 1997-04-14
AU644148B2 (en) 1993-12-02
ATE169219T1 (de) 1998-08-15
AU7404791A (en) 1991-10-10
EP0453127A2 (en) 1991-10-23
EP0453127B1 (en) 1998-08-05
US5686487A (en) 1997-11-11
DE69129921D1 (de) 1998-09-10
TW224942B (enExample) 1994-06-11
ES2119762T3 (es) 1998-10-16
DK0453127T3 (da) 1998-10-26
CA2039420A1 (en) 1991-10-05

Similar Documents

Publication Publication Date Title
TW224942B (enExample)
DK0559413T3 (enExample)
GR3020902T3 (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
GR3019760T3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (es) Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
SG86284A1 (en) Use of (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidineacetamide for the manufacture of medicaments for the treatment of anxiety
EP0424156A3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
GR3026105T3 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
EP0430552A3 (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
GR3022217T3 (en) Treatment of cataract with prostacyclin compounds
GR3018535T3 (en) Use of Isoxazolin-3-one Derivatives as antidepressants.
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent